Innovations in nephrology: what to remember from 2017?

Johann Morelle, Nathalie Demoulin, Michel Jadoul, Hubert Piessevaux Published in the journal : February 2018 Category : Nephrology

Summary :

In 2017, the treatment of severe forms (proteinuric and/or with impaired kidney function) of IgA nephropathy, the most common primary chronic glomerulonephritis, proved to be of particular interest. Several studies highlighted that the risks associated with conventional immunosuppressive therapy, still mainly based on corticosteroids outweighs the potential benefits. A Targeted (enteric)-release corticosteroids constitutes a new therapeutic agent will soon be tested in a Phase 3 study, following encouraging results from Phase 2. Furthermore, several observational studies, conducted in 2017, suggested that the nephrotoxicity due to proton pump inhibitors be more common than hitherto appreciated, though the causal relationship between both must still be firmly demonstrated. In this paper, we discuss the implications from these studies concerning the use of this widely prescribed family drug.

Key words

IgA Glomerulonephritis, Corticosteroids, Proteinuria, Proton Pump Inhibitor, Nephrotoxicity